ESCAPE is comprised of two investigational drug products: BEAM-103, an anti-CD117 monoclonal antibody that is designed to suppress and/or eliminate hematopoietic stem and progenitor cells that ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “A case report of donor cell–derived ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

Hematopoietic stem cell transplantation (HSCT) is a vital treatment for both malignant and non-malignant disorders in pediatric patients.

The company expects to initiate a Phase 1 healthy volunteer clinical trial of BEAM-103, an anti-CD117 monoclonal antibody (mAb) designed to suppress hematopoietic stem and progenitor cells that ...

ECTRIMS and EBMT said stem cell transplant can be considered for some with RRMS, such as those who are younger and have less ...

BEAM is also working on a preclinical program called ESCAPE, which takes the edited hematopoietic stem cells (ala BEAM-101) but uses an anti-CD117 monoclonal antibody to target diseased blood ...

Over the past 23 years, she has made innovative contributions in hematopoietic stem cell (HSC) biology, stem cell aging, epigenetic regulation of stem cells and the development of CRISPR tools for ...